Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?

Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions

(2011) Leonidas Benetatos et al.   ANNALS OF HEMATOLOGY

Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice

(2011) A. M. Ramirez-Herrick et al.   BLOOD

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

(2011) Pamela S. Becker et al.   BRITISH JOURNAL OF HAEMATOLOGY

From Plk1 to Plk5

(2011) Guillermo de Cárcer et al.   CELL CYCLE

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia

(2011) S S Farag et al.   LEUKEMIA

Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression

(2011) G. de Carcer et al.   MOLECULAR AND CELLULAR BIOLOGY

Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity

(2011) E. Agura et al.   ONCOLOGIST

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

(2011) Monika Raab et al.   Nature Communications

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

(2010) D. S. Boss et al.   ANNALS OF ONCOLOGY

Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS

(2010) Borje S. Andersson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process

(2010) L. Lordier et al.   BLOOD

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

(2010) E. Claire Dees et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2010) Anne M. Traynor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe

(2010) June-Won Cheong et al.   CANCER LETTERS

A functional link between Polo-like kinase 1 and the mammalian Target-Of-Rapamycin pathway?

(2010) Annelies G. Renner et al.   CELL CYCLE

Polo-box domain: a versatile mediator of polo-like kinase function

(2010) Jung-Eun Park et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

(2010) A S Moore et al.   LEUKEMIA

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

(2010) T. Macarulla et al.   MOLECULAR CANCER THERAPEUTICS

The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells

(2010) M. Grundy et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus

(2010) Zdenek Andrysik et al.   NUCLEIC ACIDS RESEARCH

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

Hydroxyurea and hydroxamic acid derivatives as antitumor drugs

(2009) Nina Saban et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent

(2009) Amy W. Chun et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Aurora-A and hBora Join the Game of Polo

(2009) L. Macurek et al.   CANCER RESEARCH

Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives

(2009) Shozo Yoshida et al.   CANCER TREATMENT REVIEWS

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

(2009) Puneet Chopra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study

(2009) Linda Granowetter et al.   JOURNAL OF CLINICAL ONCOLOGY

Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer

(2009) Filippo Montemurro et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

(2009) T Ikezoe et al.   LEUKEMIA

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Polo-like kinases: conservation and divergence in their functions and regulation

(2009) Vincent Archambault et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

(2008) S. Faderl et al.   BLOOD

Polo-like Kinase 3 Functions as a Tumor Suppressor and Is a Negative Regulator of Hypoxia-Inducible Factor-1  under Hypoxic Conditions

(2008) Y. Yang et al.   CANCER RESEARCH

Cell Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis Induced by Chloroquine in Human Breast Cancer Cell Line Bcap-37

(2008) Pei-du Jiang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development

(2008) Tohru Takaki et al.   CURRENT OPINION IN CELL BIOLOGY

Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia

(2008) Christine Didier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

RETRACTED: Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells

(2008) Noriyuki Takai et al.   GYNECOLOGIC ONCOLOGY

Molecular characterization of acute myeloid leukemia

(2008) K. Dohner et al.   HAEMATOLOGICA

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid

(2008) Anita Ryningen et al.   LEUKEMIA RESEARCH

Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells

(2008) A. M. D'Alise et al.   MOLECULAR CANCER THERAPEUTICS

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

(2008) Libor Macůrek et al.   NATURE

Distinct microRNA expression profiles in acute myeloid leukemia with common translocations

(2008) Z. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry

(2008) A. Seki et al.   SCIENCE